title: Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53.
abstract: It has been well known that curcumin is a powerful inhibitor of proliferation of several tumor cells. However, the molecular basis of the anti-proliferative effect of curcumin has not been investigated in detail. In this paper, we present evidence to show that curcumin inhibited proliferation of a variety of B lymphoma cells. At low concentrations curcumin inhibited the proliferation of BKS-2, an immature B cell lymphoma, more effectively than that of normal B lymphocytes and caused the apoptosis of BKS-2 cells in a dose- and time-dependent manner. Furthermore, curcumin downregulated the expression of survival genes egr-1, c-myc, and bcl-X(L) as well as the tumor suppressor gene p53 in B cells. In addition, NF-kappaB binding activity was also downregulated almost completely by curcumin. Stimulation with CpG oligonucleotides or anti-CD40 overcame growth inhibition induced by low concentrations of curcumin. Our results suggest that curcumin caused the growth arrest and apoptosis of BKS-2 immature B cell lymphoma by downregulation of growth and survival promoting genes.
authors.affiliation: Department of Microbiology and Immunology, Department of General Surgery, Lexington, Kentucky 40536, USA.
authors.forename: S S
authors.initials: SS
authors.lastname: Han
authors.forename: S T
authors.initials: ST
authors.lastname: Chung
authors.forename: D A
authors.initials: DA
authors.lastname: Robertson
authors.forename: D
authors.initials: D
authors.lastname: Ranjan
authors.forename: S
authors.initials: S
authors.lastname: Bondada
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D003474:Curcumin / Q000494:pharmacology*; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects; D051766:Early Growth Response Protein 1; D006131:Growth Inhibitors / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D017874:Immediate-Early Proteins; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D051379:Mice; D008808:Mice, Inbred CBA; D008811:Mice, Inbred DBA; D016513:Mice, SCID; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D016271:Proto-Oncogene Proteins c-myc / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D015398:Signal Transduction / Q000187:drug effects; D014157:Transcription Factors / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D051020:bcl-X Protein
chemical_list: C494812:Bcl2l1 protein, mouse; D004268:DNA-Binding Proteins; D051766:Early Growth Response Protein 1; C486109:Egr1 protein, mouse; D006131:Growth Inhibitors; D017874:Immediate-Early Proteins; D016328:NF-kappa B; D019253:Proto-Oncogene Proteins c-bcl-2; D016271:Proto-Oncogene Proteins c-myc; D014157:Transcription Factors; D016159:Tumor Suppressor Protein p53; D051020:bcl-X Protein; D003474:Curcumin